ProQR Therapeutics « Terug naar discussie overzicht

quote:

bmwr1200gs schreef op 19 november 2019 19:13:

Ik heb ze er weer uit gegooid.
Het is de laatste tijd een prachtig aandeel om te traden.
Binnen een dag (of twee) je aankoop weer eruit.
Grote kans op 50 cent in de pocket

quote:

Marble Arch schreef op 19 november 2019 21:25:

ProQR Therapeutics N.V. (PRQR) PT Lowered to $33 at Citi (was 40 USD)

twitter.com/analystwire/status/119674...

quote:

Wil Helmus schreef op 20 november 2019 11:26:

Vandaag presentaties in Londen en Boston:

Presentation at the 3rd Annual Ophthalmic Drugs Conference

A presentation will be delivered by Aniz Girach, MD, Chief Medical Officer of ProQR, during the 3rd Annual Ophthalmic Drugs Conference to be held November 19-20, 2019 in London.

Presentation Title: Antisense Oligonucleotides for Inherited Retinal Diseases
Presentation Time: Wednesday, November 20 at 1:20-2:00 p.m. GMT
Presentation at the 1st RNA Editing Summit

During the 1st RNA Editing Summit to be held on November 19-20, 2019 in Boston, MA, a presentation will be delivered by David Rodman, MD, Executive Vice President of Research and Development of ProQR.

Presentation Title: Translating RNA Editing to Our Clinical Development Pipelines
Presentation Time: Wednesday, November 20 at 9:40-10:10 a.m. EST
This presentation will highlight ProQR’s proprietary Axiomer® platform, a fully owned and in house developed RNA platform with broad applicability. ProQR is accelerating this platform for precision medicine in the retina with oligonucleotide therapeutics.

quote:

nb schreef op 20 november 2019 17:41:

Heb je herstel, zakt arwh weer....
Kl.t. v.n d. b.k

quote:

Tom3 schreef op 18 november 2019 21:31:

[...]

Omdat Arrowhead meer dan 50% van mijn portefeuille uitmaakt leek het me wenselijk het risico een beetje "te spreiden". De Arrowhead concentratie kon eigenlijk ontstaan doordat de koers van ProQR een jaar gelden door het dak ging. Nu zijn de rollen omgekeerd. Ik acht ProQR derhalve nog steeds heel kansrijk.

quote:

Marble Arch schreef op 20 november 2019 20:47:

oQR Therapeutics (NASDAQ:PRQR) had its target price reduced by analysts at Citigroup from $40.00 to $33.00 in a research note issued to investors on Tuesday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup‘s target price would suggest a potential upside of 383.87% from the company’s previous close.
A number of other research firms have also recently commented on PRQR. Zacks Investment Research upgraded shares of ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a report on Wednesday, August 14th. Royal Bank of Canada reiterated a “buy” rating and issued a $27.00 price target on shares of ProQR Therapeutics in a report on Sunday, August 11th. ValuEngine upgraded shares of ProQR Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of ProQR Therapeutics in a report on Friday, October 11th. Finally, BidaskClub downgraded shares of ProQR Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $25.83

americanbankingnews.com/?p=12619290

quote:

4finance schreef op 20 november 2019 21:40:

[...]

Tom3 heeft ons deze info ook al gedeeld.

quote:

Staycalm schreef op 20 november 2019 22:32:

Goed teken. 1x1 sessies zijn goed ontvangen. Geeft vertrouwen. Voorstelbaar dat we komende weken/maanden blijvend up gaan. Er is een grote onderwaardering in te halen. Op naar Q1.

quote:

nb schreef op 20 november 2019 17:41:

Heb je herstel, zakt arwh weer....
Kl.t. v.n d. b.k